Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Follow-up of Denosumab in Giant Cell Tumour of Bone (Study 20062004 Extension)
2017-001758-32Phase 4Completed
- Sponsor
- Amgen
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by Amgen. Primary endpoint: Rate of adverse events of interest. Started Aug 2017; status: completed.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on 2017-001758-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001758-32.